AsifnawazJun 1

Eli Lilly and Company Retevmo shows major reduction in cancer recurrence risk trial

#EliLilly #Retevmo #CancerResearch #ClinicalTrial
https://meyka.com/blog/eli-lilly-retevmo-cuts-cancer-recurrence-or-death-risk-by-83-in-phase-3-trial-of-151-nsclc-patients-2606/

Eli Lilly Retevmo Cuts Cancer Recurrence or Death Risk by 83% in Phase 3 Trial of 151 NSCLC Patients | Meyka

Eli Lilly's Retevmo cut cancer recurrence or death risk by 83% in the Phase 3 LIBRETTO-432 trial of 151 NSCLC patients. 24-month EFS hit 92% vs 61% on placebo. Full trial data inside.